JP2025509613A5 - - Google Patents
Info
- Publication number
- JP2025509613A5 JP2025509613A5 JP2024554864A JP2024554864A JP2025509613A5 JP 2025509613 A5 JP2025509613 A5 JP 2025509613A5 JP 2024554864 A JP2024554864 A JP 2024554864A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2025509613 A5 JP2025509613 A5 JP 2025509613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- approximately
- administered
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320347P | 2022-03-16 | 2022-03-16 | |
| US63/320,347 | 2022-03-16 | ||
| US202263340726P | 2022-05-11 | 2022-05-11 | |
| US63/340,726 | 2022-05-11 | ||
| PCT/US2023/064550 WO2023178255A1 (en) | 2022-03-16 | 2023-03-16 | Combinations comprising metap2 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509613A JP2025509613A (ja) | 2025-04-11 |
| JP2025509613A5 true JP2025509613A5 (enExample) | 2026-03-26 |
Family
ID=85979451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554864A Pending JP2025509613A (ja) | 2022-03-16 | 2023-03-16 | がん治療のためのＭｅｔＡＰ２阻害剤を含む組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260014194A1 (enExample) |
| EP (1) | EP4493181A1 (enExample) |
| JP (1) | JP2025509613A (enExample) |
| KR (1) | KR20240164549A (enExample) |
| CN (1) | CN119300818A (enExample) |
| AU (1) | AU2023235307A1 (enExample) |
| CA (1) | CA3245962A1 (enExample) |
| MX (1) | MX2024011197A (enExample) |
| WO (1) | WO2023178255A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201700832YA (en) * | 2014-08-04 | 2017-03-30 | Merck Patent Gmbh | Pyrrolidinone derivatives as metap-2 inhibitors |
| CN113453721B (zh) * | 2018-10-26 | 2025-09-16 | 辛德弗雷克斯公司 | Metap2抑制剂的生物标志物及其应用 |
-
2023
- 2023-03-16 WO PCT/US2023/064550 patent/WO2023178255A1/en not_active Ceased
- 2023-03-16 CA CA3245962A patent/CA3245962A1/en active Pending
- 2023-03-16 JP JP2024554864A patent/JP2025509613A/ja active Pending
- 2023-03-16 MX MX2024011197A patent/MX2024011197A/es unknown
- 2023-03-16 US US18/846,365 patent/US20260014194A1/en active Pending
- 2023-03-16 AU AU2023235307A patent/AU2023235307A1/en active Pending
- 2023-03-16 EP EP23716148.4A patent/EP4493181A1/en active Pending
- 2023-03-16 CN CN202380040935.XA patent/CN119300818A/zh active Pending
- 2023-03-16 KR KR1020247034327A patent/KR20240164549A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009090A5 (enExample) | ||
| JP2022022264A5 (enExample) | ||
| JP2023174661A5 (enExample) | ||
| JP4297620B2 (ja) | 肝細胞性腫瘍処置用薬剤 | |
| JP2024015120A5 (enExample) | ||
| US4006224A (en) | Method and agent for treating inflammatory disorders of the gastrointestinal tract | |
| JP2011511071A5 (enExample) | ||
| JP2022509262A5 (enExample) | ||
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| EP2335731A3 (en) | Multiple-variable dose regimen for treating TNF-alpha-related disorders | |
| JP2007515469A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2019529581A5 (enExample) | ||
| JP2025509510A5 (enExample) | ||
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| JP2024530189A5 (enExample) | ||
| JP2022544485A5 (enExample) | ||
| JP2024533423A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2022534118A5 (enExample) | ||
| JP2004525143A5 (enExample) | ||
| JP2009545546A (ja) | リウマチ性疾患の遅延放出型グルココルチコイド治療 | |
| JP2020508351A5 (enExample) | ||
| JP2024506385A5 (enExample) | ||
| JP2022058873A5 (enExample) |